OBJECTIVE: To compare the efficacy of two regimens (21 active pills + 7 placebo pills vs. 24 active pills + 4 placebo pills) of combined oral contraception (COC), both containing 20 μg of ethinyl E(2) and 3 mg of drospirenone, in improving the severity of pure menstrual migraine without aura. DESIGN: Prospective randomized study. SETTING:Patients attending the gynecology department of the University of Siena for consultation regarding an appropriate contraception. PATIENT(S): Women ages 20 to 35 years (n = 60) suffering from pure menstrual migraine without aura. INTERVENTION(S): Three months of contraceptive use (ethinyl E(2) 20 μg/drospirenone 3 mg) in two different regimens: group A received 21 active + 7 placebo pills whereas group B received 24 active + 4 placebo pills. MAIN OUTCOME MEASURE(S): Monthly evaluation of the duration and severity of patients' daily headache attacks. RESULT(S): Although both study groups demonstrated significant reduction in the intensity and duration of menstrual migraine, patients in group B (24/4 COC) reported a significant reduction in the intensity and a shorter duration of their menstrual migraine, compared with group A (21/7 COC). CONCLUSION(S): The 24/4 COC regimen is recommended as the preferred treatment for patients suffering from pure menstrual migraine without aura.
RCT Entities:
OBJECTIVE: To compare the efficacy of two regimens (21 active pills + 7 placebo pills vs. 24 active pills + 4 placebo pills) of combined oral contraception (COC), both containing 20 μg of ethinyl E(2) and 3 mg of drospirenone, in improving the severity of pure menstrual migraine without aura. DESIGN: Prospective randomized study. SETTING:Patients attending the gynecology department of the University of Siena for consultation regarding an appropriate contraception. PATIENT(S): Women ages 20 to 35 years (n = 60) suffering from pure menstrual migraine without aura. INTERVENTION(S): Three months of contraceptive use (ethinyl E(2) 20 μg/drospirenone 3 mg) in two different regimens: group A received 21 active + 7 placebo pills whereas group B received 24 active + 4 placebo pills. MAIN OUTCOME MEASURE(S): Monthly evaluation of the duration and severity of patients' daily headache attacks. RESULT(S): Although both study groups demonstrated significant reduction in the intensity and duration of menstrual migraine, patients in group B (24/4 COC) reported a significant reduction in the intensity and a shorter duration of their menstrual migraine, compared with group A (21/7 COC). CONCLUSION(S): The 24/4 COC regimen is recommended as the preferred treatment for patients suffering from pure menstrual migraine without aura.
Authors: Gabriele S Merki-Feld; Bruno Imthurn; Ronald Langner; Burkhardt Seifert; Andreas R Gantenbein Journal: J Headache Pain Date: 2015-05-01 Impact factor: 7.277
Authors: Simona Sacco; Gabriele S Merki-Feld; Karen Lehrmann Ægidius; Johannes Bitzer; Marianne Canonico; Andreas R Gantenbein; Tobias Kurth; Christian Lampl; Øjvind Lidegaard; E Anne MacGregor; Antoinette MaassenVanDenBrink; Dimos-Dimitrios Mitsikostas; Rossella Elena Nappi; George Ntaios; Koen Paemeleire; Per Morten Sandset; Gisela Marie Terwindt; Kjersti Grøtta Vetvik; Paolo Martelletti Journal: J Headache Pain Date: 2018-08-31 Impact factor: 7.277